Vera Therapeutics (VERA) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic outlook and pipeline

• Preparing for commercial launch of lead candidate atacicept in IgAN with FDA priority review and PDUFA date set for July 7, 2026.

• Pipeline includes MAU868 (phase II, BK virus) and VT-109 (preclinical, immune modulation), with full ownership across all indications and geographies.

• Strong financial position with $779 million pro forma cash and access to $425 million in non-dilutive capital.

• Management team has deep experience in clinical development and commercialization.

Clinical development and efficacy data

• Atacicept demonstrated statistically significant reduction in proteinuria and robust efficacy across subgroups in phase III IgAN trial.

• Safety profile similar to placebo, with low rates of serious adverse events and high patient retention over two years.

• Long-term eGFR data to be shared in early 2027; ongoing trials (PIONEER, Extend) will provide additional data in broader patient populations.

• Atacicept is self-administered weekly via autoinjector, with high desirability among nephrologists.

Market opportunity and commercialization plans

• U.S. IgAN patient population estimated at 160,000, with half at high risk; new guidelines support earlier intervention.

• Commercial team and sales force of 82 reps being hired to target over half of 11,000 U.S. nephrologists.

• Disease state awareness and education efforts have been ongoing for years, with strong recognition among nephrologists.

• Atacicept positioned as a category-creating launch with potential for premium pricing and broad payer coverage.